IGF1 and prostate carcinoma: Although our Mendelian randomization results were unable to support previous evidence of an association between genetically predicted serum IGF-1 levels and prostate cancer risk, recent published Mendelian randomization studies reported a causal association of IGF-1 levels with prostate cancer (23, 24).